|
1
|
Usami Y, Mizobuchi Y, Ijuin M, Yamada T, Morita M, Mizuki K, Yoneyama H, Harusawa S. Synthesis of 6-Halo-Substituted Pericosine A and an Evaluation of Their Antitumor and Antiglycosidase Activities. Mar Drugs 2022; 20:md20070438. [PMID: 35877731 PMCID: PMC9323573 DOI: 10.3390/md20070438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 11/16/2022] Open
Abstract
The enantiomers of 6-fluoro-, 6-bromo-, and 6-iodopericosine A were synthesized. An efficient synthesis of both enantiomers of pericoxide via 6-bromopericosine A was also developed. These 6-halo-substituted pericosine A derivatives were evaluated in terms of their antitumor activity against three types of tumor cells (p388, L1210, and HL-60) and glycosidase inhibitory activity. The bromo- and iodo-congeners exhibited moderate antitumor activity similar to pericosine A against the three types of tumor cell lines studied. The fluorinated compound was less active than the others, including pericosine A. In the antitumor assay, no significant difference in potency between the enantiomers was observed for any of the halogenated compounds. Meanwhile, the (−)-6-fluoro- and (−)-6-bromo-congeners inhibited α-glucosidase to a greater extent than those of their corresponding (+)-enantiomers, whereas (+)-iodopericosine A showed increased activity when compared to its (−)-enantiomer.
Collapse
Affiliation(s)
- Yoshihide Usami
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
- Correspondence: ; Tel.: +81-796-90-1087; Fax: +81-796-90-1005
| | - Yoshino Mizobuchi
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Mai Ijuin
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Takeshi Yamada
- Department of Medicinal Molecular Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan;
| | - Mizuki Morita
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Koji Mizuki
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Hiroki Yoneyama
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| | - Shinya Harusawa
- Department of Pharmaceutical Organic Chemistry, Osaka University of Pharmaceutical Sciences, Nasahara 4-20-1, Takatsuki 569-1094, Osaka, Japan; (Y.M.); (M.I.); (M.M.); (K.M.); (H.Y.); (S.H.)
| |
Collapse
|